A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SR1375 in Hospitalized Adult Patients With Community-acquired Pneumonia
Latest Information Update: 03 Sep 2024
At a glance
- Drugs SR 1375 (Primary)
- Indications Community-acquired pneumonia
- Focus Therapeutic Use
- Sponsors SIMR Biotech
- 03 Sep 2024 New trial record